Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senzime ABSNZZF 69 Receivables Turnover is 1.61 as of Jun. 2026. GuruFocus rates SNZZF with a GF Score™ of 69/100 and a GF Value™ of $0.99 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Senzime AB ranks better than 64.24% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Senzime AB's Revenue for the
three
months ended in Jun. 2026 was $2.59 Mil. Senzime AB's average Accounts Receivable for the
three
months ended in Jun. 2026 was $1.61 Mil.
Hence, Senzime AB's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.61.
Senzime AB (OTCPK:SNZZF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Senzime AB Receivables Turnover Related Terms
Senzime AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Senzime AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNZZF vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Senzime AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senzime AB Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Senzime AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senzime AB (SNZZF) has a Receivables Turnover of 1.61 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Senzime AB and its competitors. According to the industry distribution chart, Senzime AB ranks #290 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 35.8%.
Is Senzime AB's Receivables Turnover too high?
Senzime AB's current Receivables Turnover is 1.61. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Senzime AB's value of 1.61 is 70.8% below this industry median. Based on the distribution chart, Senzime AB ranks #290 out of 811 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Senzime AB has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Senzime AB's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Senzime AB ranks #290 out of 811 companies for Receivables Turnover. This puts Senzime AB in the upper half of its industry. The industry median Receivables Turnover is 5.51. Senzime AB's value of 1.61 is 70.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senzime AB's current Receivables Turnover of 1.61 is 70.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Senzime AB and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senzime AB's current Receivables Turnover is 1.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senzime AB stock overvalued right now?
Based on GuruFocus' analysis, Senzime AB (SNZZF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.99, compared to a current price of $0.47 — trading 52.2% below its estimated fair value. The current Receivables Turnover is 1.61 and 70.8% below the Medical Devices & Instruments industry median of 5.51. Senzime AB's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Senzime AB (SNZZF), the current Receivables Turnover is 1.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senzime AB (SNZZF) Overvalued in 2026?
Based on GuruFocus' analysis, Senzime AB stock appears to be undervalued.
The current stock price of $0.47 is trading 52.2% below its estimated GF Value™ of $0.99.
GuruFocus considers Senzime AB to be Possible Value Trap.
Key valuation signals for SNZZF:
Receivables Turnover: 1.61
GF Value™: $0.99 vs. price of $0.47 (52.2% below fair value)
Industry Position: 70.8% below the Medical Devices & Instruments median (#290 of 811)
No single metric tells the full story. See the SNZZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
69GF Score
Get the complete analysis for SNZZF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNZZF has been successfully added to your 
